Genmab A/S Files 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Apr 22, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, corporate-action
Related Tickers: GMAB
TL;DR
Genmab A/S filed a 6-K on 4/22/24, incorporating it into their S-8 filings.
AI Summary
Genmab A/S filed a Form 6-K on April 22, 2024, to report information as a foreign private issuer. This report is incorporated by reference into Genmab's existing S-8 registration statements, which relate to employee stock plans.
Why It Matters
This filing serves to update SEC filings and is relevant for investors tracking Genmab's ongoing compliance and corporate actions.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain new financial or operational information.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-005412 (filing_id) — Accession Number
- 20240422 (date) — Filing Date
- Form 6-K (document_type) — Filing Type
- Form S-8 (document_type) — Incorporated by reference into
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed by Genmab A/S as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for the month of April 2024.
When was this Form 6-K filed?
This Form 6-K was filed on April 22, 2024.
What is the company's principal executive office address?
The address of Genmab A/S's principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Into which registration statements is this 6-K filing incorporated by reference?
This Form 6-K is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
Does Genmab A/S file annual reports under Form 20-F or Form 40-F?
Genmab A/S indicates it files annual reports under Form 20-F.
Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-04-22 16:14:33
Filing Documents
- tmb-20240422x6k.htm (6-K) — 19KB
- tmb-20240422xex99d1.htm (EX-99.1) — 63KB
- tmb-20240422xex99d1a.htm (EX-99.1(A)) — 16596KB
- tmb-20240422xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240422xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-005412.txt ( ) — 16692KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: APRIL 22, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated April 22, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix: Share Buy-Back Program Transactions April 15 to 19, 2024